The modulation of the cell-cycle: A sentinel to alert the NK cells of dangers

Frontiers in Immunology

Volumn 4, Issue OCT, 2013, Pages

  Baychelier, Florence ^a,b   Vieillard, Vincent ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Activating receptors; Cell cycle; Infections; NK cells; Stress; Tumors

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3;

CELL CYCLE; CELL CYCLE PROGRESSION; DNA DAMAGE; DNA REPLICATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MITOSIS; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84885405947     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00325     Document Type: Short Survey

References (55)

1. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol (2011) 11:645-57. doi:10.1038/nri3044.
2. Vivier E, Raulet DH, Moretta A, Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687.
3. Shibuya K, Lanier LL, Philips JH, Ochs HD, Shimizu K, Nakayama E, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity (1999) 11:615-23. doi:10.1016/S1074-7613(00)80136-3.
4. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol (2013) 4:69. doi:10.3389/fimmu.2013.00069.
5. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 31:413-41. doi:10.1146/annurev-immunol-032712-095951.
6. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 198:557-67. doi:10.1084/jem.20030788.
7. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 27:965-74. doi:10.1016/j.immuni.2007.10.010.
8. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 206:1495-503. doi:10.1084/jem.20090681.
9. Vieillard V, Strominger JL, Debré P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci U S A (2005) 102:10981-6. doi:10.1073/pnas.0504315102.
10. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P, Vieillard V. Identification of a cellular ligand for the natural killer receptor NKp44. Blood (2013). doi:10.1182/blood-2013-03-489054.
11. Reymond N, Imbert AM, Devilard E, Fabre S, Chabannon C, Xerri L, et al. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 199:1331-41. doi:10.1084/jem.20032206.
12. Bialoszewska A, Baychelier F, Niderla-Bielinska J, Czop A, Debré P, Vieillard V, et al. Constitutive expression of ligand for natural killer cell NKp44 receptor (NKp44L) by normal human articular chondrocytes. Cell Immunol (2013) 285:6-9. doi:10.1016/j.cellimm.2013.08.005.
13. Murray A, Hunt T. The Cell Cycle: An Introduction. New York: Oxford University Press (1993).
14. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol (2012) 226:352-64. doi:10.1002/path.3022.
15. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science (1989) 246:629-34. doi:10.1126/science.2683079.
16. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol (2004) 5:792-804. doi:10.1038/nrm1493.
17. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol (2007) 8:379-93. doi:10.1038/nrm2163.
18. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 9:153-66. doi:10.1038/nrc2602.
19. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev (1997) 11:3471. doi:10.1101/gad.11.24.3471.
20. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev (2000) 14:2393-409. doi:10.1101/gad.813200.
21. Nolte-'t Hoen EN, Almeida CR, Cohen NR, Nedvetzki S, Yarwood H, Davis DM. Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication. Blood (2007) 109:670-3. doi:10.1182/blood-2006-07-036509.
22. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PLoS One (2007) 2:e1339. doi:10.1371/journal.pone.0001339.
23. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 9:785-97. doi:10.1038/nrc2696.
24. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med (2012) 209:2409-22. doi:10.1084/jem.20120565.
25. Liu XV, Ho SS, Tan JJ, Kamran N, Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol (2012) 189:1826-34. doi:10.4049/jimmunol.1200965.
26. El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol (2013) 191:1509-15. doi:10.4049/jimmunol.1301071.
27. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 436:1186-90. doi:10.1038/nature03884.
28. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood (2007) 110:606-15. doi:10.1182/blood-2006-10-052720.
29. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of NK cell receptors. Nat Rev Immunol (2009) 9:568-80. doi:10.1038/nri2604.
30. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev (2006) 214:130-42. doi:10.1111/j.1600-065X.2006.00460.x.
31. Madar S, Goldstein I, Rotter V. Did experimental biology die? Lessons from 30 years of p53 research. Cancer Res (2009) 69:6378-80. doi:10.1158/0008-5472.CAN-09-0940.
32. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res (2011) 71:5998-6009. doi:10.1158/0008-5472.CAN-10-3211.
33. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 10:1321-8. doi:10.1038/nm1146.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-8. doi:10.1126/science.1092472.
35. Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, et al. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood (2013) 122:684-93. doi:10.1182/blood-2013-02-482513.
36. Sinclair A, Yarranton S, Schelcher C. DNA-damage response pathways triggered by viral replication. Expert Rev Mol Med (2006) 8:1-11. doi:10.1017/S1462399406010544.
37. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol (2005) 5:835-43. doi:10.1038/nri1760-c1.
38. Jost S, Altfeld M. Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect (2012) 14:904-15. doi:10.1016/j.micinf.2012.05.001.
39. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem (2003) 278:25879-86. doi:10.1074/jbc.M303948200.
40. Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 4:65-71. doi:10.1038/nm0198-065.
41. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle (2007) 6:182-8. doi:10.4161/cc.6.2.3732.
42. Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, et al. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog (2009) 5:e1000613. doi:10.1371/journal.ppat.1000613.
43. Lopez-Soto A, Quinones-Lombrana A, Lopez-Arbesu R, Lopez-Larrea C, Gonzalez S. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem (2006) 281:30419-30. doi:10.1074/jbc.M604868200.
44. Ndolo T, Dhillon NK, Nguyen H, Guadalupe M, Mudryj M, Dandekar S. Simian immunodeficiency virus Nef protein delays the progression of CD4+ T cells through G1/S phase of the cell cycle. J Virol (2002) 76:3587-95. doi:10.1128/JVI.76.8.3587-3595.2002.
45. Fausther-Bovendo H, Sol-Foulon N, Candotti D, Agut H, Schwartz O, Debré P, et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS (2009) 23:1077-87. doi:10.1097/QAD.0b013e32832cb26b.
46. Madrid AS, Ganem D. Kaposi's sarcoma-associated herpesvirus ORF54/dUTPase downregulates a ligand for the NK activating receptor NKp44. J Virol (2012) 86:8693-704. doi:10.1128/JVI.00252-12.
47. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4 T cells via OX40-OX40 ligand interactions. J Immunol (2004) 173:3716-24.
48. Barber MA, Zhang T, Gagne BA, Sentman CL. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J Immunol (2007) 178:6140-7.
49. Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Front Immunol (2012) 3:408. doi:10.3389/fimmu.2012.00408.
50. Ardolino M, Zingoni A, Cerboni C, Cecere F, Soriani A, Iannitto ML, et al. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood (2011) 117:4778-86. doi:10.1182/blood-2010-08-300954.
51. Yamamoto K, Fujiyama Y, Andoh A, Bamba T, Okabe H. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta (2001) 1526:10-2. doi:10.1016/S0304-4165(01)00099-X.
52. Trivedi PP, Roberts PC, Wolf NA, Swanborg RH. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol (2005) 174:4590-7.
53. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol (2011) 187:5693-702. doi:10.4049/jimmunol.1102267.
54. Horton NC, Mathew SO, Mathew PA. Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS One (2013) 8:e59552. doi:10.1371/journal.pone.0059552.
55. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL. Viral evasion of natural killer cells. Nat Immunol (2002) 3:1006-12. doi:10.1038/ni1102-1006.